吲哚酚磷酸酯 | 13822-19-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 中文名称: 吲哚酚磷酸酯
• 英文名称: Indoxyl phosphate
• 英文别名: 1H-indol-3-yl dihydrogen phosphate
• CAS: 13822-19-0
• 化学式: C₈H₈NO₄P
• 分子量: 213.13
• InChiKey: JTNGEYANGCBZLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

文献信息

• Prodrugs of piperazine and substituted piperidine antiviral agents
  申请人：Ueda Yasutsugu

  公开号：US20050209246A1

  公开（公告）日：2005-09-22

  This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R 1 does not exist; W is C or N with the proviso that when W is N, R 2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C 1 -C 6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

  这项发明提供了前药化合物I，其药物组成物以及它们在治疗HIV感染中的用途。 其中： X为C或N，但当X为N时，R1不存在； W为C或N，但当W为N时，R2不存在；V为C；E为氢或其药用可接受盐；以及 Y从以下组中选择： 此外，这项发明提供了制备前药化合物I的有用中间体化合物II。 其中： L和M独立地选自C1-C6烷基，苯基，苯甲基，三烷基硅基，-2,2,2-三氯乙氧基和2-三甲基硅基乙氧基的组。
• Inhibitors of signal transduction and activator of transcription 3
  申请人：McMurray S. John

  公开号：US20070010428A1

  公开（公告）日：2007-01-11

  Stat3 inhibitor compounds are disclosed, wherein the compounds are structural analogs of Ac-pTyr-Leu-Pro-Gln-Thr-NH 2 and bind to the SH2 domain of Stat3 under physiological conditions to inhibit a cellular signaling activity of Stat3.

  抑制剂化合物Stat3被披露，其中这些化合物是Ac-pTyr-Leu-Pro-Gln-Thr-NH2的结构类似物，并在生理条件下与Stat3的SH2结构域结合，从而抑制Stat3的细胞信号活性。
• [EN] INDOLE-CONTAINING COMPOUNDS WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY<br/>[FR] COMPOSES CONTENANT DE L'INDOLE A ACTIVITE ANTI-TUBULINE ET DE CIBLAGE VASCULAIRE
  申请人：UNIV BAYLOR

  公开号：WO2004099139A1

  公开（公告）日：2004-11-18

  Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin assembly. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

  已发现了取代三甲氧基苯基吲哚配体，这些配体表现出令人印象深刻的细胞毒性，以及抑制微管组装的显著能力。这类化合物以及相关衍生物是治疗人类癌症的优秀临床候选药物。此外，这些配体中的某些作为前药，很可能被证明是肿瘤选择性血管靶向化疗药物，或具有靶向血管活性，从而选择性地预防和/或破坏非恶性增殖的血管系统。
• [EN] PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS<br/>[FR] PRODROGUES DE PIPERAZINE ET AGENTS ANTIVIRAUX DE PIPERIDINE SUBSTITUEE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005090367A1

  公开（公告）日：2005-09-29

  This invention provides for prodrug Compounds (I), pharmaceutical compositions thereof, and their use in treating HIV infection. Also, this invention provides for intermediate Compounds (II) useful in making prodrug Compounds (I).

  本发明提供了前药化合物（I），其制药组合物以及在治疗HIV感染中使用的方法。此外，本发明还提供了制备前药化合物（I）有用的中间体化合物（II）。
• Indole-containing compounds with anti-tubulin and vascular targeting activity
  申请人：Pinney G. Kevin

  公开号：US20070082872A1

  公开（公告）日：2007-04-12

  Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin assembly. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

  发现了取代三甲氧基苯基吲哚配体，它们表现出令人印象深刻的细胞毒性以及抑制微管蛋白组装的显著能力。这些化合物以及相关衍生物是治疗人类癌症的优秀临床候选药物。此外，这些配体中的某些作为前药可能证明是肿瘤选择性血管靶向化学治疗药物或具有血管靶向活性，从而选择性预防和/或破坏非恶性增殖血管。